In 2023, Wuhan CANVEST Biotechnology Co set up its operations in the Beijing Cell Therapy Transformation Platform in the Daxing part of the Beijing Daxing International Airport Economic Zone.
This high-tech company specializes in integrating biotechnology services and research and development. The company's primary focus is on providing quality testing for a wide range of cells, including recombinant cells, virus host cells, stem cells, and immune cells, as well as strains, toxins, and raw materials for production enterprises and research institutions.
Additionally, it offers services for virus clearance process validation technology and the establishment and preservation of cell banks.
The company has developed a cell quality testing technology system that involves nearly 100 technologies and a unique database system, and has served over 700 domestic and international enterprises to date.